



ITATECH e le politiche equity investments per il finanziamento del trasferimento tecnologico in Italia

Workshop «Il Trasferimento Tecnologico:
opportunità, finanziamenti e valutazione»,
Pisa 27 Novembre 2017



EIF & Tech Transfer

What is the EIF?

“

We provide
risk financing
to stimulate
entrepreneurship
and innovation
in Europe

”

OBJECTIVE

To support **smart, sustainable** and **inclusive** growth for the benefit of European SMEs


HOW

By offering a wide range of **targeted products to support SMEs and mid-caps**, ranging from venture capital to guarantees and microfinance

WHERE

Working with financial intermediaries across the **EU-28 and EFTA countries, candidate and potential candidate countries**

EIF helps businesses at every stage of their development



TT investments seek to bridge gap between research & market

R&D


Technology Transfer
“technology IP”

Marketable Product
“prototype IP”

University /
Research
Organisation



IP / Idea



Spin-out, licensing, collaboration
(contract research)

Market



Research organisations and their TTOs can seize opportunities to increase and catalyse their competitiveness for innovation

Engage with industry, develop partnerships, and encourage contract research

Build networks to meet economic reality; inward looking vs. outward

Outsource with qualified and experienced partners willing to work in close collaboration

Identify and work with trusted (fund) managers who can help select the best opportunities with commercialisation potential


Become active participants in long-term TT vehicles / funds

Research organisations to provide commitments for participating in TT structures, financially and / or with other resources

TT & IP Investments



	Year	Investment	Country	Fund Size
	TT & IP Funds			EUR m
1	2006	Leuven CD3 (Centre for Drug design and Discovery)	Belgium	8
2	2006	IP Venture Fund	UK	37
3	2008	Chalmers Innovation Seed Fund	Sweden	17
4	2008	Manchester UMIP Premier Fund	UK	38
5	2009	Karolinska Development	Sweden	36
6	2010	Leuven CD3 II (Centre for Drug design and Discovery)	Belgium	16
7	2011	Louvain Vives II	Belgium	43
8	2011	Telecom Technologies Transfert (3T)	France	21
9	2012	Demeter Cleantech seed fund	France	45
10	2012	Elaia Alpha fund	France	46
11	2012	Cancer Research Tech (CRT) Pioneer Fund (a)	UK	30
12	2013	Emertec 5	France	51
13	2013	Epidarex II (formerly Rock Spring)	UK	58
14	2013	INRIA IT Translation	France	30
15	2013	IP Venture Fund II	UK	36
16	2013	Grand Ouest d'Amorcage Sante	France	57
17	2013	Auriga Bioseeds IV	France	42
18	2013	SINTEF Venture IV	Norway	27
19	2014	Cancer Research Tech (CRT) Pioneer Fund (b)	UK	30
20	2014	Diffusion Capital	Turkey	30
21	2014	Kurma Diagnostics	France	35
22	2015	ACT TTA Fund	Turkey	23
23	2015	Abingworth Pharma Co-development Fund	UK	102
24	2015	V-Bio Ventures	Belgium	73
25	2015	Thuja	Netherlands	30
26	2015	Quadrivium	France	56
27	2015	BeAble	Spain	35
28	2016	UCL Technology Fund	UK	70
29	2016	Carduso	Netherlands	31
30	2016	CD3 III	Belgium	60
31	2016	University Bridge Fund	Ireland	61
32	2017	GO Capital II*	France	80
33	2017	Advent France Biotechnology*	France	70
34	2017	Innovation Industries	Netherlands	75
35	2017	Vertis Venture 3 Tech Tfr Fund	Italy	40
36	2017	[in progress - Q4 2017 closing]	EU / EFTA	50
37	2017	[in progress - Q4 2017 closing]	EU / EFTA	40
38	2017	[in progress - Q4 2017 closing]	EU / EFTA	100
TOTAL				1,728




Some statistics

Innovation and R&D > Technology Transfer Gap

- The inventiveness of Europe's leading economies is also reflected in terms of patent filing activity
- Although Italy ranks **7th worldwide** in terms of **scientific papers** production, the delay in terms of total number of patent applications filed in a year is much more evident
- In 2015 **Italy** has in fact filed about 4,000 patent applications at the European Patent Office (+ 9% vs. 2014 but **less than 50%** compared to France)
- United States, Germany, France and Japan confirm instead the right interconnection between scientific production and patent activity

Number of European patent applications filed with the EPO (2015)



- ✓ This **huge gap** highlights the potential scope for scientific research in Italy to turn into **Technology Transfer opportunities**, especially considering a still vibrant and competitive manufacturing environment
- ✓ To close the gap with the main comparable economies, **Italy should double the resources for investments in innovation**, with the obvious need to effectively combine public and private resources in order to achieve a greater diffusion of innovation in the entrepreneurial ecosystem

Innovation and R&D > Technology Transfer Gap



Rank	Country	Value (H-Index) ¹
1	United Kingdom	1,015.00
2	United States of America	1,648.00
3	Germany	887.00
4	France	811.00
5	Canada	794.00
6	Japan	745.00
7	Italy	713.00
8	Netherlands	694.00
9	Switzerland	686.00
10	Australia	644.00
11	Sweden	614.00
12	Spain	591.00
13	Belgium	547.00
14	Denmark	518.00
15	Israel	496.00
16	China	495.00
17	Austria	449.00
18	Finland	443.00
19	Korea	424.00
20	Norway	402.00
21	Russian Federation	390.00
22	India	383.00
23	Brazil	379.00
24	Poland	371.00
25	Hong Kong (China)	359.00
26	New Zealand	351.00
27	Singapore	349.00
28	Ireland	332.00
29	Greece	326.00
30	Hungary	301.00

Rank	Countries	VC investments (\$/mln)
1	United States	59.698,50
2	Total Europe	4.220,13
3	Canada	1.825,63
4	Israel (2014)	1.165,00
5	Japan (2014)	1.105,29
6	Korea	1.087,46
7	United Kingdom	951,93
8	Germany	928,47
9	France	757,86
10	South Africa (2014)	352,72
11	Switzerland	289,29
12	Australia	288,49
13	Sweden	180,84
14	Netherlands	180,50
15	Spain	173,55
16	Austria	122,87
17	Finland	118,19
18	Denmark	86,34
19	Ireland	84,03
20	Belgium	68,30
21	Portugal	65,08
22	Norway	62,20
23	Russian Federation	59,00
24	Italy	51,33
25	New Zealand	43,59
26	Hungary	27,67
27	Poland	21,72
28	Slovak Republic	9,91
29	Luxembourg	5,94
30	Estonia	4,12


GAP

- In Italy there is a **stark contrast** between the **high quality of research and vibrant manufacturing environment** versus a level of commercialisation of R&D much lower than the EU average
- While Italy ranks **7th worldwide** in terms of production of **scientific papers**, it only occupies the **24th position** in terms of total **venture capital (VC) investments** (a proxy for innovation finance), presenting a very significant gap relative to peer countries like France and Germany
- Although Venture Capital investments do not necessarily derive from TT initiatives, they represent a good proxy of the level of development of the ecosystem for innovation and of how much basic research is translated into commercial activities
- There is a poor dissemination of the "**public procurement**" innovation (according to the World Economic Forum, Italy is at the **114th place in the world in terms of public demand for technologically advanced products** and fragmentation of spending on a variety of subjects that limit the necessary economies of scale)
- **Corporate and Large Corporate are still not sufficiently geared towards open innovation and have R&D rates lower than competitors of the most advanced countries**

The gap becomes apparent by comparing not only the R&D investments, but also the patent filing activity of most OECD Countries....


Sources: Entrepreneurship at a Glance, 2016 – OECD 2016
Global Index Innovation 2016

(1) The h-index is an author-level metric that attempts to measure both the productivity and citation impact of the publications of a scientist or scholar. The index is based on the set of the scientist's most cited papers and the number of citations that they have received in other publications



- **Venture Capital investments** represent the **ability** of a country to **invest in R&D** and in Innovation to support the birth of new enterprises
- In the majority of OECD Countries, investments in **Venture Capital** account for a small percentage of GDP – the average value is about **0.05%**
- **Israel** and the **United States**, countries in which the venture capital industry is more developed and in which investments account for **0.4% and 0.3% of GDP respectively**, are an exception
- In **Italy**, venture capital investments as a percentage of GDP is **only** about **0.003%**
- **Italy shows a huge gap** of venture capital investments compared to others European countries – above all France, United Kingdom and Germany

II “market failure”





TT in Italy and ITAtech

Current TT funding options

- Own resources
- Grants
- Traditional VC
- Contract research
- Internal PoC funds

A joint initiative by Cassa Depositi e Prestiti (CDP) and the European Investment Fund (EIF) to finance technological transfer and innovation fostering growth in Italy


In Italy there is a **stark contrast** between the **high quality of research and vibrant manufacturing environment** versus a level of commercialisation of R&D much lower than the EU average

Vision




Improving the Italian innovation ecosystem through the commercialisation of **Italian research into products and services** which are used for the concrete benefit of society

Mission



The **first Equity Investment Platform in Italy** fully dedicated to the development of Technology Transfer to establish ad hoc investment funds

Objectives



- Accelerate the **commercialisation of Italian R&D**
- Foster the establishment of many **leading professional TT teams**
- Generate **economic returns** for all the stakeholders involved
- Develop a TT ecosystem through **partnerships with market participants**

ITAtech is an ambitious, highly selective Investment Platform supporting areas of excellence who wants to play a useful role as an agent for change inside and around academic institutions




EIF, part of the EIB Group, is the **specialist provider of risk finance to benefit SMEs across Europe**, by designing, promoting and implementing equity and debt financial instruments. In technology transfer in Europe EIF has financed more than 30 dedicated investment funds totaling about 1,5Bn.



CDP is the Italian Development Institution with the mission to promote the development of national economic-industrial system. CDP finances activities to support national growth through postal savings products under state guarantee and the issuance of bonds.




- **CDP and EIF have joined forces** in the area of **equity investments** in Italy, financing SMEs, Mid-Caps and innovation
- EIF and CDP are firmly convinced that the development of adequate financial instruments for funding innovation across different stages is considered an important pillar of the country competitiveness
- Under their partnership, the first initiative that CDP and EIF have launched is the **“ITAtch Platform”**, whose co-financing Agreement has been signed on 16th December 2016. Through ITAtch, CDP and EIF will jointly provide **up to EUR 200 m** to finance **a dedicated investment program in the field of technology transfer**



Confirmed investment/agreement

Possible investment/agreement

TT investment models (examples)



Investment process and indicative timelines

9-12 mths

First Screening

**Second
Screening**

Due Diligence

**Board
Approval**

**Understand
concept**

Based on preliminary
questionnaire / concept
note

**Investment
readiness**

Physical meeting
(typically in
Luxembourg),
opportunity to
articulate investment
opportunity,
understand EIF

**Stress testing
and verification**

EIF team conducts on
site visits (min. 2
days). May, or may not
lead to term sheet

**Legal
documentation**

After EIF BoD
approval, legal docs
drafted on behalf of
Manager. EIF review
Importance of legal
counsel


Investment considerations





Conclusions

First Results



Vertis Venture 3 Technology Transfer

Fondo chiuso di Venture Capital




Compagnia
di San Paolo



Lessons learnt/critical points

- Access to good science
- Close collaboration of investment vehicle with TTO; Build trust
- IP adequately protected under relevant legislation
- Incentives to managers - alignment of interests with long-term focus, up to 15-20yrs
- Min critical size ca. EUR 30m.
- Spin-out is not the only route
- “One size fits all” TT policies do not work
- Support from highest levels within research organisations
- Presence of an entrepreneurial systems beyond the research setting



Thank you for your attention